FDA
-
-
-
-
-
-
-
Genentech to Present Extensive Data Showcasing Its Industry-Leading Ophthalmology Portfolio at ARVO 2026
-
-
-
-
-
-
-
Roche gets FDA clearance for two new laboratory analytical units
-
-
-
-
-
-
-
FDA approves Genentech's Venclexta plus acalabrutinib for CLL treatment
-
-
-
-
-
-
-
Roche announces U.S. launch of next-generation cobas 6800/8800 systems and software, enhancing laboratory efficiency and testing capabilities
-
-
-
-
-
-
-
Genentech’s Tecentriq Showed Significant Overall and Disease-Free Survival Benefits in Bladder Cancer With ctDNA-Guided Treatment
-
-
-
-
-
-
-
FDA approves Genentech's Tecentriq plus lurbinectedin for lung cancer
-
-
-
-
-
-
-
Genentech’s Susvimo Maintains Vision Over Five Years With Two Refills Per Year in People With Wet Age-Related Macular Degeneration (AMD)
-
322,084 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

